Article Versions Notes

Brade AM, Bahig H, Bezjak A, Juergens RA, Lynden C, Marcoux N, Melosky B, Schellenberg D, Snow S. Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process. Current Oncology. 2024; 31(11):6512-6535. https://doi.org/10.3390/curroncol31110483

Brade, Anthony M., Houda Bahig, Andrea Bezjak, Rosalyn A. Juergens, Charmaine Lynden, Nicolas Marcoux, Barbara Melosky, Devin Schellenberg, and Stephanie Snow. 2024. "Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process" Current Oncology 31, no. 11: 6512-6535. https://doi.org/10.3390/curroncol31110483

Brade, A. M., Bahig, H., Bezjak, A., Juergens, R. A., Lynden, C., Marcoux, N., Melosky, B., Schellenberg, D., & Snow, S. (2024). Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process. Current Oncology, 31(11), 6512-6535. https://doi.org/10.3390/curroncol31110483